Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer

Cell Reports(2021)10.1016/j.celrep.2021.109665Source: DataRank Database

Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer is a research paper published in Cell Reports (2021). On theSindex it has a DataRank of 0. It has been cited 41 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access41 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (17 grants)OA: goldTopics (16)IDs (PubMed)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (20)

Alexander T. M. Cheung ORCID,Jett Crowdis ORCID,Jake R. Conway ORCID,Sabrina Y. Camp ORCID,Stephanie A. Wankowicz ORCID

Live enrichment

PubMed:23304386

U.S. Department of Defense

Grant: R01 CA227388

U.S. Department of Defense

Grant: R37 CA222574

U.S. Department of Defense

Grant: U01 CA233100

U.S. Department of Defense

Grant: W81XWH-16-1-0431

National Cancer Institute

Grant: F31CA239347

National Cancer Institute

Grant: YIA18YOUN02

Conquer Cancer Foundation

Grant: CDA13167

Conquer Cancer Foundation

Grant: T32 GM008313

National Science Foundation

Grant: DGE1144152

National Institutes of Health

Grant: T32 CA009172

National Institutes of Health

Grant: YIA20YOUN08

National Science Foundation

Grant: 1144152

Graduate Research Fellowship Program (GRFP)

National Institutes of Health

Grant: 5R37CA222574-03

Molecular origins and evolution to chemoresistance in germ cell tumors

National Institutes of Health

Grant: 1U01CA233100-01

Molecular and immune drivers of immunotherapy responsiveness in prostate cancer

National Institutes of Health

Grant: 5F31CA239347-02

Redefining the Molecular Landscape of Melanoma

National Institutes of Health

Grant: 5T32CA009172-21

GRADUATE TRAINING IN CANCER RESEARCH

National Institutes of Health

Grant: 5R01CA227388-03

Integrative Somatic and Germline Computational Biology to Redefine Clinical Actionability in Solid Tumors

goldLicense: cc-by-nc-nd

publisherhttps://doi.org/10.1016/j.celrep.2021.109665

publisherhttps://api.elsevier.com/content/article/PII:S2211124721011098?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2211124721011098?httpAccept=text/plain

http://www.cell.com/article/S2211124721011098/pdf

https://doi.org/10.1101/2021.04.20.440657

Fields of Study

0301 basic medicine0303 health sciences03 medical and health sciences

Keywords

MaleProstatectomyRiskAntineoplastic Agents, HormonalNuclear ProteinsProstatic NeoplasmsAndrogen AntagonistsProstate-Specific AntigenNeoadjuvant TherapyRepressor ProteinsAdaptor Proteins, Vesicular TransportAntineoplastic Combined Chemotherapy ProtocolsHumans

Sustainable Development Goals

SDG 3: 3. Good health